InvestorsHub Logo
Followers 137
Posts 22853
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Friday, 10/05/2018 1:05:09 PM

Friday, October 05, 2018 1:05:09 PM

Post# of 807
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.

https://www.cellbiomedgroup.com/newsroom/cbmg-enters-into-strategic-licensing-and-collaboration-agreement-with-a-global-leader-in-car-t-cell-therapy-for-patients-in-china?lang=en

Good luck and GOD bless,

George